Celldex Therapeutics
CLDX
180 hedge funds and large institutions have $1.75B invested in Celldex Therapeutics in 2021 Q4 according to their latest regulatory filings, with 42 funds opening new positions, 59 increasing their positions, 49 reducing their positions, and 21 closing their positions.
121% more call options, than puts
Call options by funds: $95.1M | Put options by funds: $43M
100% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 21
20% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 49
13% more funds holding
Funds holding: 160 → 180 (+20)
6.27% more ownership
Funds ownership: 92.5% → 98.77% (+6.3%)
24% less capital invested
Capital invested by funds: $2.3B → $1.75B (-$545M)
36% less funds holding in top 10
Funds holding in top 10: 11 → 7 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$60.3M |
| 2 |
EP
Eversept Partners
New York
|
+$25.8M |
| 3 |
State Street
Boston,
Massachusetts
|
+$22.3M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$12.5M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$12.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$38.3M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$14.2M |
| 3 |
CC
Commodore Capital
New York
|
-$13.4M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$13.1M |
| 5 |
VA
VR Adviser
New York
|
-$10.2M |
CLDX Hedge Fund Activity: Q4 2021 in Review
180 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q4 2021, worth a combined $1.75B — down 24% from $2.3B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new CLDX positions and 21 closed out — a net gain of 21 holders — while 59 added to existing stakes and 49 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $60.3M. The largest seller was Redmile Group, cutting an estimated $38.3M.
- 180 institutional investors held Celldex Therapeutics (CLDX) as of Q4 2021, up from 160 in Q3 2021.
- Funds reported $1.75B of Celldex Therapeutics stock for Q4 2021, down 24% quarter-over-quarter.
- 42 funds opened new Celldex Therapeutics positions in Q4 2021 and 21 closed out, a net change of +21 holders.
- The largest Celldex Therapeutics buyer in Q4 2021 was Fidelity Investments, an estimated $60.3M added.
- The largest Celldex Therapeutics seller in Q4 2021 was Redmile Group, an estimated $38.3M sold.
Based on aggregated 13F filings for Q4 2021.